TrianglePUBLICATIONS · 16293863
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2005 Nov 20
- First author
- Langley RE
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Langley RE
- type
- Author
- name
- Carmichael J
- type
- Author
- name
- Jones AL
- type
- Author
- name
- Cameron DA
- type
- Author
- name
- Qian W
- type
- Author
- name
- Uscinska B
- type
- Author
- name
- Howell A
- type
- Author
- name
- Parmar M
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Langley RE
- type
- Author
- name
- Carmichael J
- type
- Author
- name
- Jones AL
- type
- Author
- name
- Cameron DA
- type
- Author
- name
- Qian W
- type
- Author
- name
- Uscinska B
- type
- Author
- name
- Howell A
- type
- Author
- name
- Parmar M
- type
- Author
- bibliography ids
- nci-bib-994f3b682a2cdd0c86fbe6a7
- book metadata
- content sha256
- 062fbd3bf70085a3b4ce25e7c19bb1ed5073adbfe4a9d96103e0262a274039ec
- document type
- citation
- dois
- 10.1200/JCO.2005.01.1817
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:16293863
- immutable id
- pubmed:16293863@062fbd3bf70085a3b4ce25e7c19bb1ed5073adbfe4a9d96103e0262a274039ec
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- Source null
- issn print
- 0732-183X
- issue
- 33
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 8322-30
- volume
- 23
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 16293863
- provenance
- batch id
- a181c30258a88d182e78
- provider
- NCBI PubMed ESummary
- record sha256
- 03bc9d679d00b3cc3f10f37c28996fb61af0d2c83310a33f6e4a991a397e09d7
- response sha256
- 558e0dce453ae424567844b062522ebd1d27363c3312c81dbf6f32a8ff08da24
- retrieved at
- 2026-09-09T23:46:03.896343+00:00
- publication date
- display
- 2005 Nov 20
- precision
- day
- year
- 2005
- publication types
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Preserved source evidence · Not medical advice